{"brief_title": "New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)", "brief_summary": "This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)", "condition": ["Bacterial Infections"], "intervention_type": ["Drug"], "intervention_name": ["Zyvox\u00ae / Linezolid"], "criteria": "Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary. Inclusion Criteria: - Hospitalized/chronic care pediatric patients (birth through 17 years) - Known infections due to vancomycin-resistant enterococcus species, including diagnosis of hospital-acquired pneumonia, complicated skin and skin structure infections, catheter-related bacteremia, bacteremia of unidentified source, and other infections - Requires a minimum of 3 days of IV medication - Patients with mixed infections due to VRE & gram negative bacteria are allowed to enroll in the study. For most of the infections, 2 or more of additional symptoms are required. Exclusion Criteria: - Potentially effective concomitant antibiotic - A high surgical cure rate - Medical conditions which would preclude clinical evaluation or require treatment of longer duration than 28 days - 24 hours of antibiotic treatment within 48 hours of study entry (unless pre-approved) - Having an infected device that could not be removed", "gender": "All", "minimum_age": "N/A", "maximum_age": "17 Years", "healthy_volunteers": "No", "keyword": "Drug Resistance, Microbial", "mesh_term": ["Infection", "Communicable Diseases", "Bacterial Infections", "Linezolid", "Vancomycin"], "id": "NCT00035854"}